Harry traveled to the San Francisco Bay Area this summer, and while there he interviewed the co-founders of three local data-driven diagnostics and drug discovery startups, all of whom participated in the same graduate program: the Biomedical Informatics Program at Stanford's School of Medicine. Joining Harry were Aria Pharmaceuticals co-founder and CEO Andrew Radin, BigHat Biosciences co-founder and chief scientific officer Peyton Greenside, and Inflammatix co-founder and CEO Tim Sweeney. The conversation covered how each company's work to advance healthcare and therapeutics rests on data and computation, and how the ideas, skills, connections each entrepreneur picked up at Stanford have played into their startups and their careers.
The content above was previously recorded. The views herein were made at the time of this recording and are not updated to reflect changes in economic or financial circumstances. The opinions are those of the contributor and not Scientia Ventures, LLC, its affiliates, officers, or employees. Nothing herein constitutes a recommendation, solicitation, or offer to purchase securities or private funds, which can only be made through the relevant offering documents.
